DAWN
Day One Biopharmaceuticals Inc
Price Chart
No historical data available
Latest Quote
$21.53
Current Price| Open | $21.49 |
| Day High | $21.53 |
| Day Low | $21.49 |
| Volume | 2,555,688 |
Stock Information
| Shares Outstanding | 103.33M |
| Total Debt | $2.79M |
| Cash Equivalents | $441.11M |
| Revenue | $158.18M |
| Net Income | $-107.32M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.22B |
| EPS (TTM) | $-1.04 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.79B |
| Sales | $158.18M |
| Income | $-107.32M |
| Book/sh | $4.28 |
| Cash/sh | $4.27 |
| Employees | 178 |
Financial Ratios
| Quick Ratio | 7.73 |
| Current Ratio | 8.02 |
| Debt/Eq | 0.63 |
Returns & Margins
| ROA | -14.64% |
| ROE | -22.74% |
| Gross Margin | 89.12% |
| Operating Margin | -51.12% |
| Profit Margin | -67.85% |
Ownership
| Insider Ownership | 16.82% |
| Institutional Ownership | 83.49% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -504.10 |
| P/S | 14.06 |
| P/B | 5.03 |
Analyst Data
| Recommendation | none |
| Target Price | $21.50 |
Technical Indicators
| SMA20 | $21.47 |
| SMA50 | $18.42 |
| SMA200 | $10.80 |
| RSI | 65.22 |
| ATR | 0.0264 |
| Shares Float | 71.35M |
| Short Float | 7.49% |
| Short Ratio | 2.79 |
| Volatility | -1.75 |
Performance History
| Week | +0.28% |
| Month | +0.75% |
| Quarter | +80.17% |
| 6 Months | +196.56% |
| YTD | +143.28% |
| Year | +189.38% |
| 3 Years | +69.93% |
| 10 Years | -16.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About Day One Biopharmaceuticals Inc
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. As of April 22, 2026, Day One Biopharmaceuticals, Inc. operates as a subsidiary of Servier Pharmaceuticals LLC.
đ° Latest News
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum
Simply Wall St. âĸ 2026-03-12T08:10:15Z
Oracle, Nike upgraded: Wall Street's top analyst calls
The Fly âĸ 2026-03-11T13:40:55Z
Here Are Wednesdayâs Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More
24/7 Wall St. âĸ 2026-03-11T11:45:54Z
Here Are Tuesdayâs Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Loweâs, Qualcomm, Rivian, Strategy and More
24/7 Wall St. âĸ 2026-03-10T12:06:24Z
Servierâs $2.5B cancer bet underlines a quick oncology growth strategy
Pharma Voice âĸ 2026-03-10T08:00:00Z
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Zacks âĸ 2026-03-09T13:10:00Z
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen
MarketBeat âĸ 2026-03-09T10:34:09Z
Day One (DAWN) Soars 100% on $2.5-Billion Merger
Insider Monkey âĸ 2026-03-08T01:31:32Z
Servierâs US$2.5b Deal Caps Day One Biopharmaâs Oncology Upside
Simply Wall St. âĸ 2026-03-07T20:07:29Z
Investing.comâs stocks of the week
Investing.com âĸ 2026-03-07T09:30:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $17,210,000 | $5,279,000 | $0 | $0 |
| Cost Of Revenue | $17,210,000 | $5,279,000 | $0 | $0 |
| Total Revenue | $158,182,000 | $131,161,000 | $0 | $0 |
| Operating Revenue | $158,182,000 | $131,161,000 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $285,932,000 | $348,431,000 | $206,064,000 | $146,909,000 |
| Other Income Expense | $18,452,000 | $128,918,000 | $17,147,000 | $4,728,000 |
| Other Non Operating Income Expenses | $-19,000 | $109,217,000 | $-40,000 | $-18,000 |
| Operating Expense | $268,722,000 | $343,152,000 | $206,064,000 | $146,909,000 |
| General And Administrative Expense | - | - | $75,543,000 | $61,291,000 |
| Net Non Operating Interest Income Expense | - | - | - | $4,746,000 |
| Total Other Finance Cost | - | - | - | $-4,746,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Normalized Income | $-125,460,522 | $-111,059,790 | $-206,104,000 | $-146,927,000 |
| Net Income From Continuing And Discontinued Operation | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Total Operating Income As Reported | $-127,750,000 | $-217,270,000 | $-206,064,000 | $-146,909,000 |
| Net Income Common Stockholders | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Net Income | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Net Income Including Noncontrolling Interests | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Net Income Continuous Operations | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Pretax Income | $-109,298,000 | $-88,352,000 | $-188,917,000 | $-142,181,000 |
| Operating Income | $-127,750,000 | $-217,270,000 | $-206,064,000 | $-146,909,000 |
| Gross Profit | $140,972,000 | $125,882,000 | $0 | $0 |
| Net Interest Income | - | - | - | $4,746,000 |
| Per Share | ||||
| Diluted EPS | - | $-1.02 | $-2.37 | $-2.17 |
| Basic EPS | - | $-1.02 | $-2.37 | $-2.17 |
| Other | ||||
| Tax Effect Of Unusual Items | $332,478 | $4,137,210 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-142,435,000 | $-234,942,000 | $-222,868,000 | $-151,124,000 |
| Total Unusual Items | $18,471,000 | $19,701,000 | $17,187,000 | $4,746,000 |
| Total Unusual Items Excluding Goodwill | $18,471,000 | $19,701,000 | $17,187,000 | $4,746,000 |
| Reconciled Depreciation | $3,786,000 | $2,029,000 | $383,000 | $531,000 |
| EBITDA (Bullshit earnings) | $-123,964,000 | $-215,241,000 | $-205,681,000 | $-146,378,000 |
| EBIT | $-127,750,000 | $-217,270,000 | $-206,064,000 | $-146,909,000 |
| Diluted NI Availto Com Stockholders | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Tax Provision | $-1,976,000 | $7,144,000 | $0 | $0 |
| Gain On Sale Of Security | $18,471,000 | $19,701,000 | $17,187,000 | $4,746,000 |
| Research And Development | $148,135,000 | $227,702,000 | $130,521,000 | $85,618,000 |
| Selling General And Administration | $120,587,000 | $115,450,000 | $75,543,000 | $61,291,000 |
| Diluted Average Shares | - | $93,234,195 | $79,773,004 | $65,466,773 |
| Basic Average Shares | - | $93,234,195 | $79,773,004 | $65,466,773 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Minority Interests | - | - | $0 | $0 |
| Other Gand A | - | - | $75,543,000 | $61,291,000 |
Fetched: 2026-04-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $423,142,000 | $487,121,000 | $346,540,000 | $332,039,000 |
| Total Assets | $507,827,000 | $582,788,000 | $376,048,000 | $349,062,000 |
| Total Non Current Assets | $22,728,000 | $20,458,000 | $774,000 | $1,188,000 |
| Other Non Current Assets | $230,000 | $121,000 | $214,000 | $469,000 |
| Goodwill And Other Intangible Assets | $18,020,000 | $15,630,000 | $0 | - |
| Other Intangible Assets | $18,020,000 | $15,630,000 | - | - |
| Current Assets | $485,099,000 | $562,330,000 | $375,274,000 | $347,874,000 |
| Other Current Assets | $3,680,000 | $4,367,000 | $2,352,000 | $1,006,000 |
| Prepaid Assets | $7,245,000 | $9,046,000 | $6,575,000 | $4,599,000 |
| Inventory | $6,326,000 | $3,321,000 | $0 | - |
| Receivables | $26,735,000 | $13,876,000 | $0 | - |
| Accounts Receivable | $26,735,000 | $13,876,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $441,113,000 | $531,720,000 | $366,347,000 | $342,269,000 |
| Cash And Cash Equivalents | $197,078,000 | $124,968,000 | $230,784,000 | $85,262,000 |
| Non Current Prepaid Assets | - | - | - | $469,000 |
| Debt | ||||
| Total Debt | $2,793,000 | $2,602,000 | $408,000 | $813,000 |
| Long Term Debt And Capital Lease Obligation | $2,619,000 | $2,592,000 | $0 | $408,000 |
| Current Debt And Capital Lease Obligation | $174,000 | $10,000 | $408,000 | $405,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $66,665,000 | $80,037,000 | $29,508,000 | $17,023,000 |
| Total Non Current Liabilities Net Minority Interest | $6,143,000 | $6,586,000 | $0 | $408,000 |
| Other Non Current Liabilities | $484,000 | $761,000 | - | - |
| Non Current Deferred Liabilities | $3,040,000 | $3,233,000 | $0 | - |
| Current Liabilities | $60,522,000 | $73,451,000 | $29,508,000 | $16,615,000 |
| Other Current Liabilities | $672,000 | $1,237,000 | $1,041,000 | $179,000 |
| Current Deferred Liabilities | $2,000,000 | $1,554,000 | $0 | - |
| Payables And Accrued Expenses | $57,676,000 | $70,650,000 | $28,059,000 | $16,031,000 |
| Payables | $3,733,000 | $8,228,000 | $2,576,000 | $260,000 |
| Total Tax Payable | $0 | $4,966,000 | - | - |
| Accounts Payable | $3,733,000 | $3,262,000 | $2,576,000 | $260,000 |
| Equity | ||||
| Common Stock Equity | $441,162,000 | $502,751,000 | $346,540,000 | $332,039,000 |
| Total Equity Gross Minority Interest | $441,162,000 | $502,751,000 | $346,540,000 | $332,039,000 |
| Stockholders Equity | $441,162,000 | $502,751,000 | $346,540,000 | $332,039,000 |
| Gains Losses Not Affecting Retained Earnings | $65,000 | $84,000 | $9,000 | $-71,000 |
| Other Equity Adjustments | $65,000 | $84,000 | $9,000 | $-71,000 |
| Retained Earnings | $-661,403,000 | $-554,081,000 | $-458,585,000 | $-269,668,000 |
| Other | ||||
| Ordinary Shares Number | $102,982,700 | $101,116,162 | $87,227,132 | $73,458,176 |
| Share Issued | $102,982,700 | $101,116,162 | $87,227,132 | $73,458,176 |
| Tangible Book Value | $423,142,000 | $487,121,000 | $346,540,000 | $332,039,000 |
| Invested Capital | $441,162,000 | $502,751,000 | $346,540,000 | $332,039,000 |
| Working Capital | $424,577,000 | $488,879,000 | $345,766,000 | $331,259,000 |
| Capital Lease Obligations | $2,793,000 | $2,602,000 | $408,000 | $813,000 |
| Total Capitalization | $441,162,000 | $502,751,000 | $346,540,000 | $332,039,000 |
| Additional Paid In Capital | $1,102,490,000 | $1,056,738,000 | $805,107,000 | $601,771,000 |
| Capital Stock | $10,000 | $10,000 | $9,000 | $7,000 |
| Common Stock | $10,000 | $10,000 | $9,000 | $7,000 |
| Non Current Deferred Revenue | $3,040,000 | $3,233,000 | $0 | - |
| Long Term Capital Lease Obligation | $2,619,000 | $2,592,000 | $0 | $408,000 |
| Current Deferred Revenue | $2,000,000 | $1,554,000 | $0 | - |
| Current Capital Lease Obligation | $174,000 | $10,000 | $408,000 | $405,000 |
| Current Accrued Expenses | $53,943,000 | $62,422,000 | $25,483,000 | $15,771,000 |
| Net PPE | $4,478,000 | $4,707,000 | $560,000 | $719,000 |
| Gross PPE | $4,478,000 | $4,707,000 | $560,000 | $719,000 |
| Other Properties | $4,478,000 | $4,707,000 | $560,000 | $719,000 |
| Finished Goods | $1,993,000 | $873,000 | - | - |
| Work In Process | $4,333,000 | $2,448,000 | - | - |
| Raw Materials | $0 | $0 | - | - |
| Other Short Term Investments | $244,035,000 | $406,752,000 | $135,563,000 | $257,007,000 |
| Accumulated Depreciation | - | - | - | $-6,000 |
| Leases | - | - | - | $26,000 |
| Machinery Furniture Equipment | - | - | - | $0 |
| Properties | - | - | - | $0 |
| Minority Interest | - | - | - | - |
| Preferred Stock | - | - | - | - |
Fetched: 2026-04-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-107,577,000 | $-152,382,000 | $-150,077,000 | $-109,900,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-103,757,000 | $-78,113,000 | $-146,853,000 | $-109,874,000 |
| Cash Flow From Continuing Operating Activities | $-103,757,000 | $-78,113,000 | $-146,853,000 | $-109,874,000 |
| Operating Gains Losses | $71,000 | $-108,000,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-3,820,000 | $-74,269,000 | $-3,224,000 | $-26,000 |
| Investing Cash Flow | $174,648,000 | $-230,994,000 | $128,378,000 | $-255,074,000 |
| Cash Flow From Continuing Investing Activities | $174,648,000 | $-230,994,000 | $128,378,000 | $-255,074,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $178,177,000 | $161,409,000 | $161,610,000 |
| Financing Cash Flow | $1,219,000 | $203,291,000 | $163,997,000 | $165,901,000 |
| Cash Flow From Continuing Financing Activities | $1,219,000 | $203,291,000 | $163,997,000 | $165,901,000 |
| Net Common Stock Issuance | $0 | $178,177,000 | $161,409,000 | $161,610,000 |
| Common Stock Issuance | $0 | $178,177,000 | $161,409,000 | $161,610,000 |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $4,749,000 | $1,898,000 | $0 | $0 |
| End Cash Position | $197,078,000 | $124,968,000 | $230,784,000 | $85,262,000 |
| Beginning Cash Position | $124,968,000 | $230,784,000 | $85,262,000 | $284,309,000 |
| Changes In Cash | $72,110,000 | $-105,816,000 | $145,522,000 | $-199,047,000 |
| Proceeds From Stock Option Exercised | $1,219,000 | $25,114,000 | $2,588,000 | $4,291,000 |
| Net Investment Purchase And Sale | $178,436,000 | $-264,725,000 | $131,602,000 | $-255,048,000 |
| Sale Of Investment | $874,247,000 | $393,891,000 | $575,440,000 | $139,158,000 |
| Purchase Of Investment | $-695,811,000 | $-658,616,000 | $-443,838,000 | $-394,206,000 |
| Net Intangibles Purchase And Sale | $-3,500,000 | $35,900,000 | $-3,000,000 | $0 |
| Sale Of Intangibles | $0 | $108,000,000 | $0 | $0 |
| Purchase Of Intangibles | $-3,500,000 | $-72,100,000 | $-3,000,000 | $0 |
| Net PPE Purchase And Sale | $-288,000 | $-2,169,000 | $-224,000 | $-26,000 |
| Sale Of PPE | $32,000 | $0 | $0 | - |
| Purchase Of PPE | $-320,000 | $-2,169,000 | $-224,000 | $-26,000 |
| Change In Working Capital | $-28,942,000 | $26,480,000 | $9,418,000 | $6,564,000 |
| Change In Other Working Capital | $253,000 | $4,787,000 | - | - |
| Change In Other Current Liabilities | $-309,000 | $488,000 | $-405,000 | $-347,000 |
| Change In Payables And Accrued Expense | $-15,539,000 | $42,787,000 | $12,890,000 | $7,757,000 |
| Change In Accrued Expense | $-16,010,000 | $42,101,000 | $10,574,000 | $9,241,000 |
| Change In Payable | $471,000 | $686,000 | $2,316,000 | $-1,484,000 |
| Change In Account Payable | $471,000 | $686,000 | $2,316,000 | $-1,484,000 |
| Change In Prepaid Assets | $2,372,000 | $-4,463,000 | $-3,067,000 | $-846,000 |
| Change In Inventory | $-2,860,000 | $-3,243,000 | $0 | $0 |
| Change In Receivables | $-12,859,000 | $-13,876,000 | $0 | $0 |
| Changes In Account Receivables | $-12,859,000 | $-13,876,000 | $0 | $0 |
| Stock Based Compensation | $44,388,000 | $48,263,000 | $39,341,000 | $27,242,000 |
| Amortization Of Securities | $-15,738,000 | $-6,389,000 | $-10,078,000 | $-2,030,000 |
| Depreciation Amortization Depletion | $3,786,000 | $2,029,000 | $383,000 | $531,000 |
| Depreciation And Amortization | $3,786,000 | $2,029,000 | $383,000 | $531,000 |
| Amortization Cash Flow | $3,110,000 | $1,470,000 | $0 | $0 |
| Amortization Of Intangibles | $3,110,000 | $1,470,000 | $0 | $0 |
| Depreciation | $676,000 | $559,000 | $383,000 | $531,000 |
| Gain Loss On Sale Of PPE | $71,000 | $-108,000,000 | $0 | $0 |
| Net Income From Continuing Operations | $-107,322,000 | $-95,496,000 | $-188,917,000 | $-142,181,000 |
| Other Non Cash Items | - | $55,000,000 | $3,000,000 | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-04-24